| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Fusion | 37 | 2023 | 146 | 7.550 |
Why?
|
| Cervical Vertebrae | 24 | 2024 | 114 | 6.290 |
Why?
|
| Lumbar Vertebrae | 29 | 2023 | 125 | 6.030 |
Why?
|
| Spondylosis | 12 | 2021 | 14 | 5.740 |
Why?
|
| Minimally Invasive Surgical Procedures | 28 | 2016 | 70 | 5.630 |
Why?
|
| Spinal Cord Diseases | 10 | 2024 | 31 | 5.240 |
Why?
|
| Thoracic Vertebrae | 18 | 2016 | 67 | 4.840 |
Why?
|
| Magnetic Resonance Imaging | 24 | 2025 | 819 | 4.180 |
Why?
|
| Neurosurgical Procedures | 14 | 2021 | 220 | 3.830 |
Why?
|
| Spine | 10 | 2024 | 61 | 3.550 |
Why?
|
| Decompression, Surgical | 11 | 2024 | 76 | 3.420 |
Why?
|
| Spinal Fractures | 11 | 2018 | 41 | 2.820 |
Why?
|
| Middle Aged | 87 | 2025 | 7138 | 2.740 |
Why?
|
| Postoperative Complications | 20 | 2020 | 611 | 2.710 |
Why?
|
| Humans | 158 | 2025 | 28099 | 2.700 |
Why?
|
| Diskectomy | 11 | 2020 | 21 | 2.690 |
Why?
|
| Spinal Cord Compression | 6 | 2024 | 20 | 2.600 |
Why?
|
| Male | 97 | 2025 | 13492 | 2.290 |
Why?
|
| Spinal Diseases | 8 | 2024 | 43 | 2.270 |
Why?
|
| Female | 96 | 2025 | 15157 | 2.180 |
Why?
|
| Spinal Cord | 8 | 2024 | 209 | 2.090 |
Why?
|
| Retrospective Studies | 44 | 2025 | 2546 | 2.020 |
Why?
|
| Spinal Cord Neoplasms | 8 | 2020 | 35 | 1.860 |
Why?
|
| Adult | 60 | 2025 | 7740 | 1.850 |
Why?
|
| Patient Readmission | 8 | 2020 | 103 | 1.830 |
Why?
|
| Aged | 55 | 2025 | 5400 | 1.780 |
Why?
|
| Molecular Dynamics Simulation | 4 | 2021 | 40 | 1.630 |
Why?
|
| Cervical Cord | 3 | 2020 | 5 | 1.450 |
Why?
|
| Treatment Outcome | 38 | 2025 | 2379 | 1.430 |
Why?
|
| Spinal Stenosis | 4 | 2022 | 15 | 1.380 |
Why?
|
| Machine Learning | 3 | 2021 | 84 | 1.300 |
Why?
|
| Spinal Osteophytosis | 2 | 2019 | 5 | 1.260 |
Why?
|
| Vancomycin | 4 | 2022 | 58 | 1.240 |
Why?
|
| Spinal Neoplasms | 6 | 2017 | 39 | 1.170 |
Why?
|
| Astrocytes | 3 | 2024 | 77 | 1.090 |
Why?
|
| Pedicle Screws | 3 | 2021 | 13 | 1.080 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 2 | 2024 | 49 | 1.070 |
Why?
|
| Orthopedic Procedures | 4 | 2015 | 27 | 1.040 |
Why?
|
| Paraspinal Muscles | 3 | 2024 | 10 | 1.000 |
Why?
|
| Surgical Wound Infection | 7 | 2020 | 105 | 0.980 |
Why?
|
| Length of Stay | 7 | 2025 | 229 | 0.960 |
Why?
|
| Ear, External | 1 | 2025 | 13 | 0.960 |
Why?
|
| Ferritins | 2 | 2024 | 27 | 0.950 |
Why?
|
| Anti-Bacterial Agents | 5 | 2022 | 524 | 0.940 |
Why?
|
| Respiration, Artificial | 1 | 2025 | 41 | 0.940 |
Why?
|
| Peptides | 3 | 2022 | 288 | 0.930 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2025 | 41 | 0.930 |
Why?
|
| Range of Motion, Articular | 7 | 2019 | 63 | 0.920 |
Why?
|
| Epidermolysis Bullosa | 1 | 2024 | 2 | 0.920 |
Why?
|
| Elective Surgical Procedures | 4 | 2020 | 70 | 0.920 |
Why?
|
| Radiculopathy | 3 | 2014 | 9 | 0.920 |
Why?
|
| Dental Care for Children | 1 | 2024 | 6 | 0.910 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2021 | 33 | 0.880 |
Why?
|
| Anti-HIV Agents | 1 | 2024 | 20 | 0.870 |
Why?
|
| Prospective Studies | 12 | 2024 | 1248 | 0.870 |
Why?
|
| Aged, 80 and over | 19 | 2025 | 2021 | 0.860 |
Why?
|
| Pseudarthrosis | 1 | 2023 | 6 | 0.860 |
Why?
|
| Nerve Net | 1 | 2025 | 106 | 0.850 |
Why?
|
| Brain | 3 | 2025 | 741 | 0.810 |
Why?
|
| Young Adult | 20 | 2025 | 2733 | 0.800 |
Why?
|
| Biological Products | 1 | 2023 | 65 | 0.790 |
Why?
|
| Probability | 2 | 2021 | 78 | 0.790 |
Why?
|
| Coronary Artery Disease | 1 | 2025 | 217 | 0.790 |
Why?
|
| Benchmarking | 4 | 2024 | 33 | 0.790 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 37 | 0.750 |
Why?
|
| Radiosurgery | 6 | 2011 | 84 | 0.740 |
Why?
|
| Fingers | 2 | 2020 | 16 | 0.730 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2021 | 5 | 0.730 |
Why?
|
| Biomechanical Phenomena | 7 | 2017 | 180 | 0.720 |
Why?
|
| Staphylococcal Infections | 1 | 2022 | 84 | 0.720 |
Why?
|
| Research Design | 2 | 2024 | 184 | 0.710 |
Why?
|
| Disease Management | 4 | 2015 | 88 | 0.710 |
Why?
|
| Essential Tremor | 3 | 2025 | 4 | 0.710 |
Why?
|
| Gray Matter | 2 | 2024 | 24 | 0.710 |
Why?
|
| Patient Participation | 1 | 2021 | 56 | 0.700 |
Why?
|
| Trigeminal Neuralgia | 5 | 2011 | 13 | 0.690 |
Why?
|
| Evidence-Based Medicine | 5 | 2025 | 145 | 0.690 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 45 | 0.680 |
Why?
|
| Touch | 1 | 2020 | 12 | 0.670 |
Why?
|
| Upper Extremity | 1 | 2020 | 29 | 0.670 |
Why?
|
| Proteins | 2 | 2020 | 252 | 0.660 |
Why?
|
| Activities of Daily Living | 3 | 2025 | 106 | 0.660 |
Why?
|
| Atlases as Topic | 1 | 2019 | 3 | 0.660 |
Why?
|
| Oxidative Stress | 1 | 2024 | 668 | 0.650 |
Why?
|
| Hand | 1 | 2019 | 26 | 0.640 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 356 | 0.640 |
Why?
|
| Hematoma, Epidural, Spinal | 3 | 2017 | 9 | 0.630 |
Why?
|
| Kyphosis | 2 | 2016 | 19 | 0.620 |
Why?
|
| Spinal Injuries | 2 | 2019 | 13 | 0.610 |
Why?
|
| Pandemics | 5 | 2024 | 186 | 0.610 |
Why?
|
| Databases, Factual | 8 | 2020 | 253 | 0.600 |
Why?
|
| Spinal Cord Injuries | 3 | 2020 | 56 | 0.590 |
Why?
|
| Bone Screws | 5 | 2014 | 42 | 0.590 |
Why?
|
| Fluoroscopy | 2 | 2016 | 34 | 0.580 |
Why?
|
| Adolescent | 13 | 2025 | 3122 | 0.570 |
Why?
|
| Reoperation | 8 | 2020 | 145 | 0.570 |
Why?
|
| Blood Transfusion | 2 | 2017 | 77 | 0.570 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2017 | 474 | 0.560 |
Why?
|
| Chordoma | 1 | 2017 | 8 | 0.560 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2017 | 10 | 0.560 |
Why?
|
| Anemia | 1 | 2017 | 43 | 0.550 |
Why?
|
| Bone Morphogenetic Protein 2 | 2 | 2015 | 29 | 0.550 |
Why?
|
| Aging | 1 | 2025 | 968 | 0.550 |
Why?
|
| Adipose Tissue | 1 | 2018 | 183 | 0.530 |
Why?
|
| Video Recording | 2 | 2013 | 39 | 0.530 |
Why?
|
| Preoperative Period | 1 | 2016 | 15 | 0.530 |
Why?
|
| Anesthesiology | 1 | 2016 | 19 | 0.520 |
Why?
|
| Ultrasonography | 1 | 2017 | 241 | 0.520 |
Why?
|
| Surveys and Questionnaires | 6 | 2025 | 971 | 0.500 |
Why?
|
| Health Status | 1 | 2016 | 148 | 0.480 |
Why?
|
| Seroma | 1 | 2015 | 4 | 0.480 |
Why?
|
| Laminectomy | 3 | 2013 | 30 | 0.480 |
Why?
|
| Injury Severity Score | 2 | 2019 | 121 | 0.470 |
Why?
|
| Hydrocephalus | 3 | 2020 | 52 | 0.460 |
Why?
|
| Back Pain | 1 | 2014 | 20 | 0.460 |
Why?
|
| Choroid Plexus | 2 | 2020 | 6 | 0.460 |
Why?
|
| Urinary Incontinence | 1 | 2014 | 20 | 0.460 |
Why?
|
| Clinical Trials as Topic | 4 | 2024 | 214 | 0.450 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 79 | 0.450 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2014 | 37 | 0.450 |
Why?
|
| Critical Care | 2 | 2020 | 49 | 0.440 |
Why?
|
| United States | 10 | 2024 | 2146 | 0.440 |
Why?
|
| Central Cord Syndrome | 1 | 2013 | 1 | 0.420 |
Why?
|
| Brain Neoplasms | 3 | 2012 | 301 | 0.410 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2021 | 251 | 0.410 |
Why?
|
| Athletic Injuries | 1 | 2014 | 120 | 0.410 |
Why?
|
| Artificial Intelligence | 3 | 2024 | 53 | 0.410 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 129 | 0.410 |
Why?
|
| Cohort Studies | 7 | 2020 | 887 | 0.400 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2013 | 72 | 0.400 |
Why?
|
| Child | 5 | 2025 | 2242 | 0.400 |
Why?
|
| Intraoperative Care | 1 | 2012 | 22 | 0.400 |
Why?
|
| Tarlov Cysts | 1 | 2012 | 2 | 0.400 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 30 | 0.400 |
Why?
|
| Checklist | 1 | 2012 | 22 | 0.400 |
Why?
|
| Intermittent Claudication | 1 | 2014 | 117 | 0.390 |
Why?
|
| Demography | 2 | 2023 | 93 | 0.390 |
Why?
|
| Ependymoma | 3 | 2020 | 11 | 0.390 |
Why?
|
| Plasmacytoma | 1 | 2012 | 5 | 0.380 |
Why?
|
| Tuberculosis, Spinal | 1 | 2012 | 4 | 0.380 |
Why?
|
| Posture | 3 | 2017 | 39 | 0.380 |
Why?
|
| ROC Curve | 3 | 2025 | 144 | 0.370 |
Why?
|
| Venous Thromboembolism | 3 | 2018 | 133 | 0.370 |
Why?
|
| Intensive Care Units | 3 | 2025 | 50 | 0.370 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 521 | 0.370 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 961 | 0.370 |
Why?
|
| Risk Factors | 10 | 2019 | 2081 | 0.360 |
Why?
|
| Glioblastoma | 1 | 2012 | 105 | 0.360 |
Why?
|
| Ossification of Posterior Longitudinal Ligament | 1 | 2011 | 1 | 0.360 |
Why?
|
| Neuroimaging | 2 | 2021 | 87 | 0.360 |
Why?
|
| Axis, Cervical Vertebra | 1 | 2010 | 2 | 0.340 |
Why?
|
| Thermodynamics | 2 | 2021 | 93 | 0.330 |
Why?
|
| Spondylolisthesis | 4 | 2015 | 11 | 0.330 |
Why?
|
| White Matter | 2 | 2020 | 89 | 0.320 |
Why?
|
| Intervertebral Disc Degeneration | 4 | 2015 | 8 | 0.320 |
Why?
|
| Quality of Life | 3 | 2025 | 487 | 0.320 |
Why?
|
| Incidence | 5 | 2021 | 562 | 0.310 |
Why?
|
| Mice, Knockout | 4 | 2024 | 848 | 0.310 |
Why?
|
| Time Factors | 8 | 2020 | 1593 | 0.310 |
Why?
|
| Neck | 2 | 2021 | 26 | 0.310 |
Why?
|
| Pulmonary Embolism | 3 | 2020 | 126 | 0.300 |
Why?
|
| Prognosis | 5 | 2020 | 803 | 0.300 |
Why?
|
| Microsurgery | 5 | 2013 | 45 | 0.290 |
Why?
|
| Child, Preschool | 3 | 2024 | 1146 | 0.290 |
Why?
|
| Surgeons | 2 | 2021 | 50 | 0.290 |
Why?
|
| Neuronal Plasticity | 2 | 2025 | 50 | 0.280 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2007 | 16 | 0.280 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 302 | 0.270 |
Why?
|
| Pain, Postoperative | 2 | 2020 | 62 | 0.270 |
Why?
|
| Michigan | 2 | 2023 | 9 | 0.270 |
Why?
|
| Functional Laterality | 2 | 2020 | 63 | 0.270 |
Why?
|
| Mice | 7 | 2024 | 4654 | 0.260 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 1013 | 0.260 |
Why?
|
| Oligodendroglia | 2 | 2023 | 15 | 0.260 |
Why?
|
| Preoperative Care | 2 | 2017 | 81 | 0.250 |
Why?
|
| Endovascular Procedures | 2 | 2019 | 70 | 0.250 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2025 | 29 | 0.250 |
Why?
|
| Internship and Residency | 3 | 2020 | 239 | 0.250 |
Why?
|
| Animals | 9 | 2024 | 10423 | 0.250 |
Why?
|
| Binding Sites | 3 | 2024 | 353 | 0.240 |
Why?
|
| Forensic Pathology | 1 | 2025 | 2 | 0.240 |
Why?
|
| Efficiency | 1 | 2025 | 18 | 0.240 |
Why?
|
| South Africa | 1 | 2025 | 19 | 0.240 |
Why?
|
| Quality Improvement | 2 | 2017 | 115 | 0.240 |
Why?
|
| Blood Loss, Surgical | 5 | 2017 | 53 | 0.240 |
Why?
|
| Hospitalization | 2 | 2025 | 198 | 0.240 |
Why?
|
| Drug Industry | 1 | 2025 | 14 | 0.240 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2025 | 4 | 0.240 |
Why?
|
| BCG Vaccine | 1 | 2025 | 14 | 0.230 |
Why?
|
| Gastrointestinal Agents | 1 | 2025 | 16 | 0.230 |
Why?
|
| Employment | 1 | 2025 | 49 | 0.230 |
Why?
|
| Area Under Curve | 2 | 2022 | 95 | 0.230 |
Why?
|
| Infant | 2 | 2024 | 1004 | 0.230 |
Why?
|
| Critical Illness | 1 | 2025 | 66 | 0.230 |
Why?
|
| Carcinoma in Situ | 1 | 2025 | 46 | 0.230 |
Why?
|
| Powders | 2 | 2014 | 19 | 0.230 |
Why?
|
| Demyelinating Diseases | 1 | 2024 | 5 | 0.230 |
Why?
|
| Crohn Disease | 1 | 2025 | 31 | 0.230 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 2024 | 1 | 0.230 |
Why?
|
| Fracture Fixation, Internal | 2 | 2015 | 34 | 0.230 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 37 | 0.230 |
Why?
|
| Endpoint Determination | 1 | 2024 | 18 | 0.220 |
Why?
|
| Disability Evaluation | 3 | 2019 | 53 | 0.220 |
Why?
|
| Intraoperative Complications | 2 | 2015 | 47 | 0.220 |
Why?
|
| Rest | 1 | 2025 | 94 | 0.220 |
Why?
|
| Hand Strength | 1 | 2024 | 38 | 0.220 |
Why?
|
| Connectome | 1 | 2025 | 87 | 0.220 |
Why?
|
| Drug Discovery | 1 | 2024 | 34 | 0.220 |
Why?
|
| Caregivers | 1 | 2025 | 118 | 0.210 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 474 | 0.210 |
Why?
|
| Drug Approval | 1 | 2023 | 10 | 0.210 |
Why?
|
| Foraminotomy | 2 | 2013 | 2 | 0.210 |
Why?
|
| Ceruloplasmin | 1 | 2023 | 9 | 0.210 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 100 | 0.210 |
Why?
|
| United States Food and Drug Administration | 1 | 2023 | 44 | 0.210 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 118 | 0.210 |
Why?
|
| Receptors, Transferrin | 1 | 2023 | 18 | 0.210 |
Why?
|
| Genome | 2 | 2021 | 56 | 0.210 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 1461 | 0.210 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 38 | 0.210 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2025 | 163 | 0.210 |
Why?
|
| Patient Discharge | 2 | 2021 | 104 | 0.200 |
Why?
|
| Multiple Sclerosis | 1 | 2023 | 87 | 0.200 |
Why?
|
| Time and Motion Studies | 1 | 2022 | 7 | 0.200 |
Why?
|
| Nomograms | 1 | 2022 | 9 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 1576 | 0.190 |
Why?
|
| Meat | 1 | 2022 | 14 | 0.190 |
Why?
|
| Gastroenterology | 1 | 2022 | 15 | 0.190 |
Why?
|
| Models, Statistical | 2 | 2020 | 128 | 0.190 |
Why?
|
| Comorbidity | 3 | 2020 | 258 | 0.190 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2021 | 19 | 0.190 |
Why?
|
| Drug Monitoring | 1 | 2022 | 36 | 0.190 |
Why?
|
| Benzamides | 1 | 2022 | 34 | 0.190 |
Why?
|
| Immunization Programs | 1 | 2022 | 14 | 0.190 |
Why?
|
| Vaccination Coverage | 1 | 2022 | 13 | 0.190 |
Why?
|
| Intervertebral Disc Displacement | 2 | 2012 | 10 | 0.190 |
Why?
|
| Head | 3 | 2017 | 18 | 0.190 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2021 | 4 | 0.190 |
Why?
|
| Piperazines | 1 | 2022 | 47 | 0.190 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 148 | 0.190 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2021 | 39 | 0.190 |
Why?
|
| Outpatients | 2 | 2020 | 44 | 0.190 |
Why?
|
| Motion | 1 | 2021 | 27 | 0.180 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2021 | 4 | 0.180 |
Why?
|
| Pharmacists | 1 | 2022 | 72 | 0.180 |
Why?
|
| Neck Muscles | 1 | 2021 | 3 | 0.180 |
Why?
|
| Musculoskeletal System | 1 | 2021 | 6 | 0.180 |
Why?
|
| Case-Control Studies | 3 | 2018 | 722 | 0.180 |
Why?
|
| Aldehydes | 1 | 2021 | 55 | 0.180 |
Why?
|
| Victoria | 1 | 2021 | 4 | 0.180 |
Why?
|
| Cholestasis | 1 | 2021 | 11 | 0.180 |
Why?
|
| Learning Curve | 1 | 2021 | 13 | 0.180 |
Why?
|
| Radiation Exposure | 1 | 2021 | 17 | 0.180 |
Why?
|
| Patient Preference | 1 | 2021 | 32 | 0.180 |
Why?
|
| Stents | 2 | 2021 | 120 | 0.180 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2020 | 3 | 0.180 |
Why?
|
| Heparin | 1 | 2021 | 111 | 0.180 |
Why?
|
| Drainage | 2 | 2018 | 45 | 0.180 |
Why?
|
| Aftercare | 1 | 2021 | 33 | 0.180 |
Why?
|
| Life Style | 1 | 2021 | 89 | 0.180 |
Why?
|
| Age Factors | 2 | 2013 | 734 | 0.180 |
Why?
|
| Teicoplanin | 1 | 2020 | 2 | 0.180 |
Why?
|
| Kinetics | 2 | 2019 | 545 | 0.180 |
Why?
|
| Incidental Findings | 1 | 2020 | 13 | 0.180 |
Why?
|
| Daptomycin | 1 | 2020 | 6 | 0.170 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 16 | 0.170 |
Why?
|
| Recovery of Function | 1 | 2021 | 118 | 0.170 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 60 | 0.170 |
Why?
|
| Neurosurgeons | 1 | 2020 | 22 | 0.170 |
Why?
|
| Sexual and Gender Minorities | 1 | 2021 | 51 | 0.170 |
Why?
|
| Mouth, Edentulous | 1 | 2020 | 6 | 0.170 |
Why?
|
| Critical Care Outcomes | 1 | 2020 | 1 | 0.170 |
Why?
|
| Longevity | 1 | 2021 | 134 | 0.170 |
Why?
|
| Dental Implants | 1 | 2020 | 11 | 0.170 |
Why?
|
| Lipids | 1 | 2021 | 208 | 0.170 |
Why?
|
| Pilot Projects | 2 | 2019 | 433 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 113 | 0.170 |
Why?
|
| Hypoxia | 1 | 2021 | 89 | 0.170 |
Why?
|
| Research Personnel | 1 | 2020 | 39 | 0.170 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 34 | 0.170 |
Why?
|
| Physical Stimulation | 1 | 2020 | 72 | 0.170 |
Why?
|
| Curriculum | 2 | 2020 | 291 | 0.160 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 36 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 39 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 91 | 0.160 |
Why?
|
| Physical Conditioning, Human | 1 | 2019 | 16 | 0.160 |
Why?
|
| Smoking | 1 | 2023 | 473 | 0.160 |
Why?
|
| Vascular System Injuries | 1 | 2019 | 19 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.160 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 371 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 385 | 0.160 |
Why?
|
| Risk | 2 | 2017 | 137 | 0.160 |
Why?
|
| Survival Rate | 3 | 2020 | 430 | 0.160 |
Why?
|
| Neurosurgery | 1 | 2020 | 75 | 0.160 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2018 | 6 | 0.150 |
Why?
|
| Severity of Illness Index | 3 | 2025 | 452 | 0.150 |
Why?
|
| Community Participation | 1 | 2019 | 26 | 0.150 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 55 | 0.150 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2019 | 52 | 0.150 |
Why?
|
| Information Dissemination | 1 | 2019 | 37 | 0.150 |
Why?
|
| Cell Differentiation | 2 | 2023 | 407 | 0.150 |
Why?
|
| Radiography | 4 | 2015 | 202 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 112 | 0.150 |
Why?
|
| Skilled Nursing Facilities | 1 | 2018 | 3 | 0.150 |
Why?
|
| Anticoagulants | 2 | 2018 | 294 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2019 | 46 | 0.150 |
Why?
|
| Algorithms | 1 | 2021 | 430 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 21 | 0.150 |
Why?
|
| Lordosis | 2 | 2015 | 6 | 0.150 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 19 | 0.150 |
Why?
|
| Hydrodynamics | 1 | 2018 | 9 | 0.150 |
Why?
|
| Internal Medicine | 1 | 2018 | 28 | 0.150 |
Why?
|
| Remission Induction | 2 | 2025 | 53 | 0.150 |
Why?
|
| Ions | 1 | 2018 | 19 | 0.150 |
Why?
|
| Rheology | 1 | 2018 | 22 | 0.150 |
Why?
|
| Home Care Services | 1 | 2018 | 37 | 0.150 |
Why?
|
| Intestinal Perforation | 1 | 2018 | 15 | 0.150 |
Why?
|
| Biopsy | 2 | 2017 | 206 | 0.140 |
Why?
|
| Scoliosis | 2 | 2015 | 34 | 0.140 |
Why?
|
| Plastics | 1 | 2017 | 6 | 0.140 |
Why?
|
| Recurrence | 3 | 2011 | 322 | 0.140 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2017 | 4 | 0.140 |
Why?
|
| Telemedicine | 1 | 2021 | 174 | 0.140 |
Why?
|
| Endoscopy, Digestive System | 1 | 2017 | 19 | 0.140 |
Why?
|
| Eukaryotic Cells | 1 | 2017 | 10 | 0.140 |
Why?
|
| Mutagenesis | 1 | 2017 | 46 | 0.140 |
Why?
|
| Spinal Curvatures | 1 | 2017 | 9 | 0.140 |
Why?
|
| Nanotechnology | 1 | 2018 | 68 | 0.140 |
Why?
|
| Metals | 1 | 2017 | 41 | 0.140 |
Why?
|
| Inpatients | 1 | 2018 | 56 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2017 | 68 | 0.140 |
Why?
|
| Pancreas | 1 | 2017 | 61 | 0.140 |
Why?
|
| Steroids | 1 | 2017 | 54 | 0.140 |
Why?
|
| Biomarkers | 1 | 2020 | 765 | 0.140 |
Why?
|
| Nanostructures | 1 | 2018 | 64 | 0.140 |
Why?
|
| Embolization, Therapeutic | 2 | 2015 | 47 | 0.130 |
Why?
|
| Administration, Topical | 2 | 2014 | 30 | 0.130 |
Why?
|
| Cellular Reprogramming | 1 | 2016 | 10 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 300 | 0.130 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2016 | 14 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2018 | 229 | 0.130 |
Why?
|
| Patients | 1 | 2016 | 17 | 0.130 |
Why?
|
| Propensity Score | 1 | 2016 | 54 | 0.130 |
Why?
|
| Sex Factors | 2 | 2020 | 466 | 0.130 |
Why?
|
| Recombinant Proteins | 2 | 2015 | 413 | 0.130 |
Why?
|
| Facial Pain | 1 | 2016 | 2 | 0.130 |
Why?
|
| Trigeminal Ganglion | 1 | 2016 | 2 | 0.130 |
Why?
|
| Pain, Intractable | 1 | 2016 | 2 | 0.130 |
Why?
|
| Postural Balance | 1 | 2016 | 41 | 0.130 |
Why?
|
| Ganglia, Parasympathetic | 1 | 2016 | 10 | 0.120 |
Why?
|
| Cadaver | 2 | 2015 | 57 | 0.120 |
Why?
|
| Models, Anatomic | 1 | 2016 | 25 | 0.120 |
Why?
|
| Foreign-Body Migration | 1 | 2015 | 8 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2016 | 134 | 0.120 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 403 | 0.120 |
Why?
|
| Hemangioblastoma | 1 | 2015 | 13 | 0.120 |
Why?
|
| Electric Stimulation Therapy | 1 | 2016 | 56 | 0.120 |
Why?
|
| Radiotherapy Dosage | 3 | 2011 | 104 | 0.120 |
Why?
|
| Atlanto-Occipital Joint | 1 | 2015 | 7 | 0.120 |
Why?
|
| Quality of Health Care | 1 | 2015 | 80 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 540 | 0.120 |
Why?
|
| Contrast Media | 2 | 2013 | 96 | 0.120 |
Why?
|
| Atlanto-Axial Joint | 1 | 2015 | 16 | 0.120 |
Why?
|
| Weight Lifting | 1 | 2014 | 49 | 0.110 |
Why?
|
| Orthotic Devices | 1 | 2014 | 7 | 0.110 |
Why?
|
| Zygapophyseal Joint | 1 | 2014 | 3 | 0.110 |
Why?
|
| MEDLINE | 1 | 2014 | 26 | 0.110 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2014 | 3 | 0.110 |
Why?
|
| PubMed | 1 | 2014 | 8 | 0.110 |
Why?
|
| Hernia | 1 | 2014 | 9 | 0.110 |
Why?
|
| Sella Turcica | 2 | 2004 | 10 | 0.110 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2013 | 5 | 0.110 |
Why?
|
| Herniorrhaphy | 1 | 2014 | 17 | 0.110 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2013 | 9 | 0.110 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2013 | 32 | 0.110 |
Why?
|
| Membrane Lipids | 1 | 2013 | 22 | 0.110 |
Why?
|
| Visual Analog Scale | 1 | 2013 | 6 | 0.110 |
Why?
|
| Neuroendoscopy | 1 | 2013 | 14 | 0.100 |
Why?
|
| Astrocytoma | 1 | 2013 | 35 | 0.100 |
Why?
|
| Ethiopia | 1 | 2013 | 9 | 0.100 |
Why?
|
| Health Planning | 1 | 2013 | 7 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2013 | 26 | 0.100 |
Why?
|
| Exercise | 1 | 2017 | 479 | 0.100 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2013 | 7 | 0.100 |
Why?
|
| Craniocerebral Trauma | 1 | 2013 | 27 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2013 | 55 | 0.100 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2012 | 13 | 0.100 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2012 | 14 | 0.100 |
Why?
|
| Meningioma | 2 | 2004 | 79 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2013 | 70 | 0.100 |
Why?
|
| Obstetrics | 1 | 2013 | 49 | 0.100 |
Why?
|
| Evoked Potentials, Motor | 1 | 2012 | 21 | 0.100 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 33 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2013 | 147 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 46 | 0.100 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2012 | 24 | 0.100 |
Why?
|
| Fatty Acids | 1 | 2013 | 206 | 0.090 |
Why?
|
| Iron | 2 | 2023 | 116 | 0.090 |
Why?
|
| Electromyography | 1 | 2012 | 175 | 0.090 |
Why?
|
| Myocardium | 1 | 2013 | 192 | 0.090 |
Why?
|
| Low Back Pain | 1 | 2011 | 28 | 0.090 |
Why?
|
| Longitudinal Ligaments | 1 | 2011 | 2 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2012 | 193 | 0.090 |
Why?
|
| Pons | 1 | 2011 | 7 | 0.090 |
Why?
|
| Hypesthesia | 1 | 2011 | 3 | 0.090 |
Why?
|
| Brain Stem | 1 | 2011 | 23 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 183 | 0.090 |
Why?
|
| Internal Fixators | 1 | 2010 | 10 | 0.080 |
Why?
|
| Cognition | 2 | 2024 | 324 | 0.080 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 65 | 0.080 |
Why?
|
| Off-Label Use | 1 | 2010 | 6 | 0.080 |
Why?
|
| Ossification, Heterotopic | 1 | 2010 | 6 | 0.080 |
Why?
|
| Prosthesis Implantation | 1 | 2010 | 26 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2010 | 41 | 0.080 |
Why?
|
| Logistic Models | 3 | 2017 | 407 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 2010 | 52 | 0.080 |
Why?
|
| Neuroma, Acoustic | 1 | 2009 | 23 | 0.080 |
Why?
|
| Ligands | 2 | 2020 | 176 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 769 | 0.080 |
Why?
|
| DNA, Fungal | 1 | 2009 | 9 | 0.080 |
Why?
|
| Liver | 1 | 2012 | 440 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2020 | 288 | 0.080 |
Why?
|
| Response Elements | 1 | 2009 | 22 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2012 | 520 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 67 | 0.080 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2009 | 25 | 0.080 |
Why?
|
| Pregnancy | 1 | 2013 | 1191 | 0.080 |
Why?
|
| Computer Simulation | 2 | 2022 | 230 | 0.070 |
Why?
|
| Glioma | 1 | 2010 | 117 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 459 | 0.070 |
Why?
|
| Pneumonia | 2 | 2020 | 89 | 0.070 |
Why?
|
| Aquaporin 1 | 1 | 2007 | 2 | 0.070 |
Why?
|
| Carbonic Anhydrases | 1 | 2007 | 6 | 0.070 |
Why?
|
| Registries | 2 | 2020 | 387 | 0.070 |
Why?
|
| Hyperplasia | 1 | 2007 | 27 | 0.070 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2009 | 112 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 330 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2020 | 391 | 0.070 |
Why?
|
| Stereotaxic Techniques | 2 | 2003 | 14 | 0.060 |
Why?
|
| Obesity | 1 | 2012 | 669 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 463 | 0.060 |
Why?
|
| Mutation | 2 | 2022 | 847 | 0.060 |
Why?
|
| Operative Time | 2 | 2016 | 41 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2013 | 991 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 490 | 0.060 |
Why?
|
| Maintenance Chemotherapy | 1 | 2025 | 17 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2004 | 15 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2025 | 68 | 0.060 |
Why?
|
| Models, Economic | 1 | 2024 | 8 | 0.060 |
Why?
|
| Sphenoid Bone | 1 | 2004 | 8 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2024 | 25 | 0.060 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2004 | 16 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2025 | 190 | 0.060 |
Why?
|
| Nasal Cavity | 1 | 2004 | 20 | 0.060 |
Why?
|
| Hallucinogens | 1 | 2024 | 14 | 0.060 |
Why?
|
| Cystectomy | 1 | 2025 | 104 | 0.050 |
Why?
|
| Palliative Care | 2 | 2021 | 82 | 0.050 |
Why?
|
| Necrosis | 2 | 2017 | 85 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 194 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2024 | 189 | 0.050 |
Why?
|
| Behavior, Animal | 1 | 2024 | 108 | 0.050 |
Why?
|
| Nimodipine | 1 | 2023 | 7 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2023 | 33 | 0.050 |
Why?
|
| Meningeal Neoplasms | 1 | 2004 | 73 | 0.050 |
Why?
|
| Motor Activity | 1 | 2024 | 148 | 0.050 |
Why?
|
| Transferrin | 1 | 2023 | 10 | 0.050 |
Why?
|
| Myelin Sheath | 1 | 2023 | 27 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 330 | 0.050 |
Why?
|
| Computational Biology | 2 | 2017 | 155 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2013 | 166 | 0.050 |
Why?
|
| Caco-2 Cells | 1 | 2022 | 6 | 0.050 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2022 | 2 | 0.050 |
Why?
|
| Digestion | 1 | 2022 | 15 | 0.050 |
Why?
|
| Imatinib Mesylate | 1 | 2022 | 14 | 0.050 |
Why?
|
| Homeostasis | 1 | 2023 | 118 | 0.050 |
Why?
|
| Pharmacies | 1 | 2022 | 19 | 0.050 |
Why?
|
| Rodentia | 1 | 2021 | 14 | 0.050 |
Why?
|
| Amino Acids | 1 | 2022 | 84 | 0.050 |
Why?
|
| Gender Identity | 1 | 2021 | 25 | 0.050 |
Why?
|
| Social Justice | 1 | 2021 | 16 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 453 | 0.050 |
Why?
|
| Vaccination | 1 | 2023 | 186 | 0.050 |
Why?
|
| Endosonography | 1 | 2021 | 37 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2022 | 125 | 0.040 |
Why?
|
| New York City | 1 | 2021 | 18 | 0.040 |
Why?
|
| Entropy | 1 | 2020 | 6 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 156 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2021 | 91 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 2020 | 19 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 14 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2012 | 29 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 167 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2020 | 27 | 0.040 |
Why?
|
| Osteomyelitis | 1 | 2020 | 14 | 0.040 |
Why?
|
| Gram-Positive Bacteria | 1 | 2020 | 33 | 0.040 |
Why?
|
| Physical Exertion | 1 | 2021 | 104 | 0.040 |
Why?
|
| Endocarditis | 1 | 2020 | 18 | 0.040 |
Why?
|
| Dental Prosthesis, Implant-Supported | 1 | 2020 | 3 | 0.040 |
Why?
|
| Dental Impression Technique | 1 | 2020 | 5 | 0.040 |
Why?
|
| Computer-Aided Design | 1 | 2020 | 14 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 60 | 0.040 |
Why?
|
| Trauma Severity Indices | 1 | 2020 | 37 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2020 | 257 | 0.040 |
Why?
|
| Workload | 1 | 2020 | 38 | 0.040 |
Why?
|
| Shoulder Injuries | 1 | 2019 | 5 | 0.040 |
Why?
|
| Health Personnel | 1 | 2020 | 95 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 120 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 148 | 0.040 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 44 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 479 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 16 | 0.040 |
Why?
|
| California | 1 | 2019 | 69 | 0.040 |
Why?
|
| Texas | 1 | 2019 | 135 | 0.040 |
Why?
|
| Mental Processes | 1 | 2018 | 16 | 0.040 |
Why?
|
| Pain | 1 | 2021 | 258 | 0.040 |
Why?
|
| House Calls | 1 | 2018 | 14 | 0.040 |
Why?
|
| Patient Safety | 1 | 2018 | 38 | 0.040 |
Why?
|
| Medication Reconciliation | 1 | 2018 | 16 | 0.040 |
Why?
|
| Diffusion | 1 | 2018 | 39 | 0.040 |
Why?
|
| Patient Admission | 1 | 2018 | 29 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 20 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2018 | 54 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2018 | 67 | 0.040 |
Why?
|
| Cervical Atlas | 1 | 2017 | 5 | 0.040 |
Why?
|
| Geriatrics | 1 | 2018 | 47 | 0.040 |
Why?
|
| Braces | 1 | 2017 | 6 | 0.040 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2017 | 2 | 0.040 |
Why?
|
| Particle Size | 1 | 2018 | 101 | 0.040 |
Why?
|
| Surface Properties | 1 | 2018 | 134 | 0.040 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2017 | 6 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2017 | 6 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2019 | 97 | 0.040 |
Why?
|
| Problem-Based Learning | 1 | 2018 | 61 | 0.040 |
Why?
|
| Yeasts | 1 | 2017 | 7 | 0.040 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 34 | 0.040 |
Why?
|
| Protein Subunits | 1 | 2017 | 44 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2017 | 32 | 0.030 |
Why?
|
| Health Surveys | 1 | 2017 | 82 | 0.030 |
Why?
|
| Physicians | 1 | 2018 | 83 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 39 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 210 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 98 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2016 | 50 | 0.030 |
Why?
|
| Transcriptome | 1 | 2017 | 214 | 0.030 |
Why?
|
| Sinusitis | 1 | 2016 | 11 | 0.030 |
Why?
|
| Neuralgia | 1 | 2016 | 18 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 2016 | 40 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 49 | 0.030 |
Why?
|
| Lumbosacral Region | 1 | 2015 | 20 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 297 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 104 | 0.030 |
Why?
|
| Prevalence | 1 | 2016 | 497 | 0.030 |
Why?
|
| Thoracoscopy | 1 | 2014 | 7 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2014 | 14 | 0.030 |
Why?
|
| Dura Mater | 1 | 2013 | 11 | 0.030 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2013 | 14 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2013 | 18 | 0.030 |
Why?
|
| Lumbosacral Plexus | 1 | 2013 | 7 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2013 | 31 | 0.030 |
Why?
|
| SEER Program | 1 | 2013 | 47 | 0.030 |
Why?
|
| Systole | 1 | 2013 | 24 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 17 | 0.030 |
Why?
|
| Self Report | 1 | 2013 | 120 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 145 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 2013 | 41 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 133 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 202 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 112 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 478 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 86 | 0.020 |
Why?
|
| Random Allocation | 1 | 2012 | 151 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 199 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 276 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 328 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 2011 | 15 | 0.020 |
Why?
|
| Myelography | 1 | 2010 | 8 | 0.020 |
Why?
|
| Vertigo | 1 | 2009 | 3 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 2010 | 12 | 0.020 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2009 | 6 | 0.020 |
Why?
|
| Cranial Nerve Diseases | 1 | 2009 | 10 | 0.020 |
Why?
|
| Tinnitus | 1 | 2009 | 6 | 0.020 |
Why?
|
| Nerve Compression Syndromes | 1 | 2010 | 13 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 659 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2009 | 54 | 0.020 |
Why?
|
| Genome, Fungal | 1 | 2009 | 7 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2009 | 26 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 99 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 632 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 194 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 269 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2010 | 161 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 343 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2009 | 174 | 0.020 |
Why?
|
| Protein Binding | 1 | 2009 | 658 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 679 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 1435 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2004 | 67 | 0.010 |
Why?
|
| Particle Accelerators | 1 | 2004 | 5 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2003 | 36 | 0.010 |
Why?
|